# Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

> **NCT03775265** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 475 (estimated)

## Conditions studied

- Bladder Urothelial Carcinoma
- Muscle Invasive Bladder Carcinoma
- Stage II Bladder Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8

## Interventions

- **DRUG:** Atezolizumab
- **PROCEDURE:** Biopsy of Bladder
- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Cystoscopy
- **DRUG:** Fluorouracil
- **DRUG:** Gemcitabine
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Mitomycin
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radiation Therapy
- **OTHER:** Survey Administration
- **PROCEDURE:** Transurethral Resection of Bladder Tumor

## Key facts

- **NCT ID:** NCT03775265
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-03
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 475 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03775265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03775265, "Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03775265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*